[go: up one dir, main page]

CL2016002839A1 - Derivados de carboxamida - Google Patents

Derivados de carboxamida

Info

Publication number
CL2016002839A1
CL2016002839A1 CL2016002839A CL2016002839A CL2016002839A1 CL 2016002839 A1 CL2016002839 A1 CL 2016002839A1 CL 2016002839 A CL2016002839 A CL 2016002839A CL 2016002839 A CL2016002839 A CL 2016002839A CL 2016002839 A1 CL2016002839 A1 CL 2016002839A1
Authority
CL
Chile
Prior art keywords
carboxamide derivatives
carboxamide
diseases
treatment
composition
Prior art date
Application number
CL2016002839A
Other languages
English (en)
Inventor
Andrew Sandham David
D'souza Anne-Marie
Ahmed Mahbud
Alexander Pulz Robert
Ann Rooney Lisa
Smith Nichola
Josef Troxler Thomas
Jagdis Bala Kamlesh
Brearley Andrew
Dale James
Porter David
Shaw Duncan
Louise Taylor Jessica
John Taylor Roger
Wrigglesworth Joe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002839(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2016002839A1 publication Critical patent/CL2016002839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE CARBOXAMIDA; COMPOSICIÓN Y COMBINACIÓN FARMACÉUTICA; Y USO EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO HIPERTENSIÓN PULMONAR Y ARTRITIS REUMATOIDE.</p>
CL2016002839A 2014-05-14 2016-11-09 Derivados de carboxamida CL2016002839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14168303 2014-05-14

Publications (1)

Publication Number Publication Date
CL2016002839A1 true CL2016002839A1 (es) 2017-01-27

Family

ID=50735903

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002839A CL2016002839A1 (es) 2014-05-14 2016-11-09 Derivados de carboxamida

Country Status (38)

Country Link
US (6) US9403810B2 (es)
EP (1) EP3143018B1 (es)
JP (1) JP6523338B2 (es)
KR (2) KR102534033B1 (es)
CN (1) CN106661012B (es)
AP (1) AP2016009550A0 (es)
AR (1) AR100440A1 (es)
AU (1) AU2015259083B2 (es)
BR (1) BR112016026552B1 (es)
CA (1) CA2948543C (es)
CL (1) CL2016002839A1 (es)
CR (1) CR20160527A (es)
CU (1) CU24434B1 (es)
CY (1) CY1124251T1 (es)
DK (1) DK3143018T3 (es)
EA (1) EA030938B1 (es)
ES (1) ES2874882T3 (es)
HR (1) HRP20210783T1 (es)
HU (1) HUE054590T2 (es)
IL (1) IL248785B (es)
JO (1) JO3610B1 (es)
LT (1) LT3143018T (es)
MA (1) MA39983B1 (es)
MX (1) MX374383B (es)
MY (1) MY186598A (es)
PE (1) PE20171443A1 (es)
PH (1) PH12016502246A1 (es)
PL (1) PL3143018T3 (es)
PT (1) PT3143018T (es)
RS (1) RS61874B1 (es)
SG (1) SG11201609217UA (es)
SI (1) SI3143018T1 (es)
SV (1) SV2016005313A (es)
TN (1) TN2016000489A1 (es)
TW (2) TWI714528B (es)
UY (1) UY36124A (es)
WO (1) WO2015175796A1 (es)
ZA (1) ZA201607658B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
JP7228595B2 (ja) * 2017-11-01 2023-02-24 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのスピロ環化合物
CN108689976B (zh) * 2018-07-23 2021-12-28 陕西师范大学 5-磺基水杨酸协同二氯二茂钛催化合成4-碘代四氢吡喃衍生物的方法
MX2023000406A (es) * 2020-07-09 2023-02-02 Bristol Myers Squibb Co Agonistas del receptor 2 del peptido formil pirazolona.
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
KR20250034289A (ko) 2022-05-02 2025-03-11 프리시릭스 엔.브이. 사전 표적화
WO2024242594A1 (ru) * 2023-05-23 2024-11-28 Общество С Ограниченной Ответственностью "Ифар" Средство для лечения легочных гипертензий

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655009A1 (de) 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
CA2376675A1 (en) * 1999-06-11 2000-12-21 The Research Foundation Of State University Of New York Antagonists of bmp and tgf.beta. signalling pathways
US7354722B1 (en) 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
EP1667983A4 (en) 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
US7291743B2 (en) 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
CN101796036A (zh) 2007-08-02 2010-08-04 欧加农股份有限公司 作为trpv1调节剂的5-苯基异噁唑-3-甲酰胺衍生物
WO2009026276A1 (en) 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011151361A1 (en) 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds
CN103380130B (zh) 2011-02-18 2015-06-17 埃科特莱茵药品有限公司 用作为食欲素拮抗剂的新颖的吡唑和咪唑衍生物
WO2015173659A2 (en) * 2014-05-14 2015-11-19 Novartis Ag Carboxamide derivatives
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas

Also Published As

Publication number Publication date
DK3143018T3 (da) 2021-05-31
SG11201609217UA (en) 2016-12-29
CY1124251T1 (el) 2022-07-22
LT3143018T (lt) 2021-06-10
KR20170003666A (ko) 2017-01-09
EA030938B1 (ru) 2018-10-31
TN2016000489A1 (en) 2018-04-04
MX374383B (es) 2025-03-06
BR112016026552A2 (pt) 2017-08-15
AU2015259083A1 (en) 2016-11-24
JP2017515853A (ja) 2017-06-15
CA2948543C (en) 2022-08-16
US20150329529A1 (en) 2015-11-19
US9403810B2 (en) 2016-08-02
WO2015175796A1 (en) 2015-11-19
BR112016026552A8 (pt) 2021-07-06
TW201946921A (zh) 2019-12-16
PE20171443A1 (es) 2017-09-29
US10195181B2 (en) 2019-02-05
JP6523338B2 (ja) 2019-05-29
MA39983B1 (fr) 2021-05-31
CN106661012A (zh) 2017-05-10
RS61874B1 (sr) 2021-06-30
KR102534033B1 (ko) 2023-05-19
SV2016005313A (es) 2018-06-12
PH12016502246B1 (en) 2017-01-09
KR20230074827A (ko) 2023-05-31
CU24434B1 (es) 2019-09-04
CN106661012B (zh) 2019-12-20
PL3143018T3 (pl) 2021-08-30
US20170014388A1 (en) 2017-01-19
AP2016009550A0 (en) 2016-11-30
EP3143018B1 (en) 2021-03-10
CU20160166A7 (es) 2017-03-03
EP3143018A1 (en) 2017-03-22
UY36124A (es) 2016-01-08
US20210052554A1 (en) 2021-02-25
PH12016502246A1 (en) 2017-01-09
TW201623296A (zh) 2016-07-01
US11672782B2 (en) 2023-06-13
ES2874882T3 (es) 2021-11-05
ZA201607658B (en) 2017-09-27
AU2015259083B2 (en) 2017-09-14
US20230301970A1 (en) 2023-09-28
IL248785B (en) 2020-04-30
MA39983A (fr) 2017-03-22
JO3610B1 (ar) 2020-08-27
CR20160527A (es) 2017-04-28
AR100440A1 (es) 2016-10-05
NZ725918A (en) 2023-09-29
EA201692300A1 (ru) 2017-04-28
HRP20210783T1 (hr) 2021-06-25
US20190381011A1 (en) 2019-12-19
US20200268718A1 (en) 2020-08-27
TWI714528B (zh) 2021-01-01
MY186598A (en) 2021-07-29
PT3143018T (pt) 2021-06-01
HUE054590T2 (hu) 2021-09-28
BR112016026552B1 (pt) 2023-02-14
MX2016014939A (es) 2017-02-28
IL248785A0 (en) 2017-01-31
CA2948543A1 (en) 2015-11-19
SI3143018T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
CL2016002839A1 (es) Derivados de carboxamida
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DK3458074T3 (da) COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2015002897A1 (es) Inhibidores de bace1
EP3116898A4 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
UA117779C2 (uk) Піразини як модулятори gpr6
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales